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Presenilins: Minireview
Genes for Life and Death
Christian Haass SEL-12 appears to be similar to PS-1 (Li and Greenwald,
1996), indicating structural as well as functional conser-Central Institute of Mental Health
Department of Molecular Biology vation of PS proteins during evolution. Although the
topology of PS-2 has not yet been worked out, it is likely68159 Mannheim
Federal Republic of Germany that PS-2 adopts a similar structure as PS-1 and SEL-
12 in view of its extensive sequence homologies.
More than 35 different mutations have been foundAlzheimer's disease (AD) is the most common neurode-
within the PS-1 gene, but only 2 mutations have beengenerative disorder worldwide, causing progressive de-
localized to the PS-2 gene (Figure 1; reviewed by Tanzimentia and death in many millions of people. AD is
et al., 1996). All FAD-associated mutations found so farcharacterized by the invariant accumulation of senile
occur at positions conserved between the human PSplaques in the brains of affected individuals. Senile
proteins, suggesting that the mutations affect function-plaques consist largely of amyloid b-peptide, which is
ally or structurally important amino acids within the pre-derived from proteolytic processing from the b-amyloid
senilins. Moreover, these amino acids are conservedprecursor protein (bAPP; reviewed by Tanzi et al., 1996).
within SEL-12 as well (Levitan and Greenwald, 1995).In the majority of cases, AD appears to occur as a spo-
The mutations are predominantly located within TM do-radic disease; however, in a substantial minority, the
mains (specifically TM2) and in the large hydrophilic loopdisease is inherited as an autosomal dominant trait (fa-
(Figure 1). All except one are missense mutations. Themilial AD or FAD). Mutations within three genes have
exceptional mutation causes a splicing error, which re-been found to cause early-onset FAD. The first muta-
sults in the elimination of exon 10 (originally called exontions were found within the bAPP gene (reviewed by
9; reviewed by Tanzi et al., 1996). Interestingly, no muta-Tanzi et al., 1996). However, mutations within the bAPP
tions have been identified that causepremature termina-gene affect only a very small number of families world-
tion of theprotein or a frameshift, suggesting that severewide. The majority of mutations were linked to a gene
structural changes in the PS proteins cannot be tol-on chromosome 14 that was recently cloned and desig-
erated.nated Presenilin (PS)-1 (Sherrington et al., 1995). A sec-
Proteolytic Processing of Presenilin Proteinsond gene (PS-2) located on chromosome 1 was cloned
When PS genes were analyzed for their protein expres-shortly thereafter (Levy-Lahad et al., 1995; Rogaev et
sion, a very interesting observation was made: endoge-al., 1995) and was shown to be responsible for some
nous PS-1 (Thinakaran et al., 1996; Podlisny et al., 1997)FAD cases as well. The integral membrane proteins en-
as well as PS-2 (Kim et al., 1997; Tomita et al., 1997)coded by PS-1 and PS-2 genes are highly homologous.
could not be found as full-length proteins; instead, abun-The identity of the proteins is z63%; within the trans-
dant proteolytic fragments of z30 kDa (N-terminal frag-membrane (TM) domains, the homology can reach 95%
ment or NTF) and z20 kDa (C-terminal fragment or CTF)(Levy-Lahad et al., 1995; Rogaev et al., 1995). Mutations
were found in all cell lines and tissues analyzed (Figurewithin the PS-1 gene are responsible for the most ag-
1). Full-length PS-1 has been observed in cells only upongressive form of FAD recorded and can cause typical
overexpression in transfected cellsand transgenic mice.AD pathology and clinical signs as early as 35 years of
Overexpression of PS results in very little if any increaseage (reviewed by Tanzi et al., 1996). These genes now
in the amount of the proteolytic fragments (Thinakaranprovide a new approach elucidating the molecular
et al., 1996). This indicates that proteolytic processingmechanisms of AD. It is therefore not surprising that
must be highly regulated, allowing only a small fractionwithin ,2 years, our understanding of the molecular and
of PS holoproteins to be processed into these frag-cellular biology of AD has made outstanding progress.
ments. This is supported by the observation that overex-The goal of this review is to summarize some of the
pression of human PS-1 in transgenic mice results inmost recent findings on the presenilins, which help to
the replacement of the endogenous mouse PS-1 frag-illuminate the molecular mechanisms leading to FAD as
ments by the proteolytic products of the human proteinwell as conventional AD.
(Thinakaran et al., 1996). The proteolytic cleavage oc-Structure and Topology of Presenilin Proteins
curs within the domain encoded by exon 10 (Figure 1),The topology of PS-1 (Figure 1) was recently worked
since the FAD-associated Dexon 10 mutation abolishesout by utilizing two strategies. First, putative TM do-
fragment formation, leading to the accumulation of full-mains were used to determine if they could export a
length PS-1 (Thinakaran et al., 1996). Radiosequencingprotease-sensitive substrate (Doan et al., 1996). Sec-
of the N-terminus of the CTF revealed that the cleavageond, cells permeabilized with the pore-forming toxin
is heterogeneous and occurs after amino acids 291, 292,streptolysine O were probed with epitope-specific anti-
and 298 (Podlisny et al., 1997). Proteolytic processingbodies (Doan et al., 1996; DeStrooper et al., 1997). These
of PS proteins appears to be a very slow process, andexperiments suggest that PS-1 probably contains six or
only minor amounts of the full-length PS proteins areeight TM domains, with both the N- and the C-terminal
turned over into the respective fragments (Thinakarandomains, as well as the large hydrophilic loop between
et al., 1996; Kim et al., 1997; Podlisny et al., 1997), indi-TM6 and TM7, oriented toward the cytoplasm (Figure
cating that a second proteolytic mechanism, indepen-1). Li and Greenwald (1996) carried out very elegant
experiments to determine the topology of the PS homo- dent of the cleavage within the domain encoded by exon
10, results in the rapid, efficient removal of PS proteinslog in C. elegans (SEL-12). The membrane orientation of
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and colleagues analyzed secreted forms of Ab in plasma
and primary fibroblast media of patients with and with-
out chromosome 14±linked FAD. These studies were
based on the observation that mutations within the
bAPP gene pathologically affect proteolytic processing
of bAPP by overproducing the longer form of Ab (Ab42;
reviewed by Tanzi et al., 1996). Ab42 is now widely be-
lieved to be the deadly player involved in AD and FAD.
The two extra amino acids cause Ab to aggregate more
rapidly, it is more toxic, and it is frequently found in
senile plaques of AD and FAD patients, although under
physiological conditions, very little Ab42 is produced
(Tanzi et al., 1996). Younkin and collaborators therefore
hypothesized that chromosome 14 mutations might also
cause elevated levels of Ab42. Indeed, it was found that
plasma and conditioned media of primary fibroblasts of
patients with chromosome 14±associated FAD con-
tained significantly elevated levels of Ab42 (Scheuner
et al., 1996). Similar results were obtained by measuring
the Ab42 concentrations in conditioned media of cells
transfected with cDNAs encoding FAD-associated PS
mutations (Borchelt et al., 1996; Citron et al., 1997;
Tomita et al., 1997; Xia et al., 1997). Therefore, all PS-1
and PS-2 mutations analyzed have been found to in-
crease Ab42 levels significantly but not Ab40. Similar
results were also obtained in transgenic mice overex-
pressing PS-1 mutations (Borchelt et al.,1996; Duff et al.,
1996; Citron et al., 1997). These results provide strong
evidence for a direct link between altered proteolytic
processing of bAPP and PS mutations causing early-
onset FAD. However, the levels of Ab42 secreted into
Figure 1. Schematic Representation of PS Proteins and the FAD culture media of cells transfected with various PS mu-
Mutations
tants do not correlate with the age of onset of clinical
Top section: the two PS-2 mutations are shown in blue. Yellow
symptoms caused by those mutations in patients. Abox (D), exon 10; HL, hydrophilic loop; and star, site of proteolytic
trivial explanation for this apparent discrepancy may becleavage of PS proteins.
the presence of genetic modifiers in individual patients.Bottom section: a small fraction (dashed arrow) of PS proteins is
proteolytically processed, which generates stable NTFs and CTFs. Nevertheless, it is striking that mutations in both of the
The majority of PS proteins (thick arrow) appear to be degraded via PS genes change bAPP metabolism in a similar manner
an ubiquitin-sensitive pathway.
as mutations within the bAPP gene, thus making it likely
that the increased production of Ab42 is indeed a cause
of early-onset FAD.(Figure 1). Indeed, recent findings demonstrate that
A Novel Mechanism for Ab Generation?PS-2 is ubiquitinated and subsequently degraded, most
Surprisingly, both PS proteins are located within thelikely by the proteasome (Kim et al., 1997). In this regard,
endoplasmic reticulum (ER) and early Golgi (Kovacs etit may be of interest that the CTF can be phosphorylated
al., 1995; Cook et al., 1996; Walter et al., 1996; Deby protein kinase C (Seeger et al., 1997; Walter et al.,
Strooper et al., 1997). In contrast, Ab generation has1997), a process that could regulate CTF metabolism or
been shown to occur late within the secretory pathwayturnover.
and later in the endocytic pathway (reviewed by TanziThe very low level of endogenous full-length PS raises
et al., 1996), which makes it difficult to understand howthe question of whether the proteolytic fragments are
the ER-localized PS proteins could affect the productionof biological or pathological relevance. A pathological
of Ab. One possibility would be that the small amountsrole is suggested by the hyperaccumulation of PS frag-
of Ab42 (which constitutes only z10% of total Ab) arements upon expression of mutant PS genes observed
generated by a proteolytic pathway that differs from thatby Tanzi and Sisodia (reviewed by Tanzi et al., 1996).
of Ab40. Such a novel mechanism is supported by theHowever, no obvious changes in fragment generation
finding that at least some Ab42 is generated by a proteo-were obtained in several human brains derived from a
lytic mechanism that does not require endosomal pro-pedigree with a PS-1 mutation (Podlisny et al., 1997).
cessing (Tienari et al., 1997). Moreover, it appears thatMutations within the Presenilin Genes
PS-2 and probably PS-1 might bind to the immatureAffect Ab Generation
(ER-localized) form of bAPP (Weidemann et al., 1997).For investigaterswho support theªamyloid hypothesis,º
Therefore, Ab42 generation may occur at least in partmutant PS genes were expected to alter proteolytic pro-
within the ER, where PS proteins are located and couldcessing of bAPP. This has indeed turned out to be the
case. Even before the PS genes were identified, Younkin interact with immature bAPP.
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The Biological and Pathological some rescuing activity (see above). Therefore, the splic-
ing mutation could exert its pathological activity by aFunctions of Presenilins
The little we know about the normal biological function different mechanism than the point mutations, a hypoth-
esis which must be proven in mammalian models exhib-of PS proteins is derived from work carried out in C.
elegans. The PS homolog in C. elegans (sel-12) was iting AD pathology.
Although work in C. elegans clearly provides impor-identified by reversion of a mutant phenotype caused
by constitutive activation of lin-12, a member of the tant insights into the functional properties of wild-type
and mutant PS proteins, it still leaves us with the obser-Notch family of cell surface receptors, implying that hu-
man PS genes might also be involved in Notch signaling vation that PS mutations in humans appear to cause
nothing but AD (reviewed by Tanzi et al., 1996), indicat-(Levitan and Greenwald, 1995). This may indeed be the
case since human PS-1 can rescueall aspects of the sel- ing that a loss of function cannot explain by itself the
pathological action of PS mutants in AD. It will be inter-12 mutant phenotype (Levitan et al., 1996; Baumeister et
al., 1997). It appears that PS-2 can also rescue the mu- esting to see the further insights that targeted deletions
of PS genes in mice will undoubtably provide.tant sel-12 phenotype (Levitan et al., 1996), suggesting
that both PS genes are involved inNotch signaling. How- A License to Kill?
A role of PS proteins in Notch signaling is not the onlyever, it cannot be ruled out that PS proteins indirectly
affect Notch signaling by interfering with the trafficking potential biological function of PS. Recent work indi-
cates that PS-2 confers apoptosis (Wolozin et al., 1996).of cell surface proteins, including the Notch receptor.
With a functional assay in hand, it was possible to It appears that overexpression of PS-2 in nerve growth
factor±differentiated PC12 cells significantly increasesdetermine whether proteolytic processing of PS-1 is a
prerequisite for its biological function. To do this, the programmed cell death initiated by trophic factor with-
drawal, which was then completely inhibited by overex-Dexon 10 PS-1 mutation was expressed in C. elegans.
As described above, this mutation was shown by Thina- pressing a PS-2 antisense RNA. Apoptosis was even
enhanced by overexpressing an FAD-associated PS-2karan et al. (1996) to inhibit proteolytic processing of
PS proteins. This mutant molecule could rescue the sel- mutation. Moreover, expressing antisense PS-2 RNA
also inhibited cell death caused by the toxic activity of12 phenotype to some extent (Levitan et al., 1996;
Baumeister et al., 1997). Moreover, it was shown that Ab. This phenomenon might be directly linked to the
neuronal pathology and cell death observed in FADthis mutation also inhibits proteolytic processing of hu-
man PS-1 in C. elegans (Baumeister et al., 1997), an cases. However, it is still controversial whether neuronal
loss during AD is indeed caused by apoptosis. Overex-observation consistent with the fact that SEL-12 under-
goes proteolytic cleavage within its large loop, like hu- pression of the highly hydrophobic PS proteins in tran-
siently transfected cells might contribute to the observedman PS (Li and Greenwald, 1996). Taken together, these
results indicate that proteolytic cleavage of PS-1 is not cell death through a nonphysiological mechanism.
AD Research at the Turn of the Centuryan absolute prerequisite for functional activity of PS-1,
although this mechanism is highly conserved during Work on the biological as well as pathological functions
of PS genes has contributed substantially to our knowl-evolution.
A deletion analysis revealed that the C-terminal do- edge of the molecular mechanisms causing AD as well
as FAD. Again, the pivotal importance of Ab42 is beingmain of PS-1 including TM7 is dispensable, while the
large cytoplasmic loop between TM6 and TM7 is neces- emphasized, since FAD-associated PS mutations in-
crease its production. Moreover, work in C. elegans pro-sary for the biological function of PS-1 (Baumeister et
al., 1997). The importance of this domain is also high- vides the first biological assay to screen for further
genes that might be involved in the prevention or en-lighted by the finding that numerous FAD-associated
mutations appear to cluster within the large loop (Sher- hancement of the molecular mechanisms causing AD.
We now must identify proteins that interact with PS.rington et al., 1995; reviewed by Tanzi et al., 1996). In
addition, one sel-12 allele (arg133) encodes a function- Such knowledge might help elucidate the molecular in-
teractions required for normal and abnormal function ofally deficient protein ending at position W381, preserv-
ing the entire large loop. One could therefore argue that PS as well as the mechanisms involved in pathological
Ab formation. Animal models exhibiting full AD pathol-the large loop has to be membrane bound by both TM
domains to maintain its biological activity. Thus, ogy will certainly contribute to these upcoming chal-
changes in the primary and/or tertiary structure of PS lenges. Therefore, the community of AD researchers will
molecules might result in a loss of function. This is sup- be busy for the foreseeable future with the remaining
ported by the interesting observation that all FAD-asso- mysteries of AD.
ciated point mutations so far analyzed exhibit a strongly
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